Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying
This trial is active, not recruiting.
|Start date||June 2014|
|End date||October 2016|
|Trial size||20 participants|
|Trial identifier||NCT02160990, 14-002683 Exenatide|
The overall goal is to determine the effect of Exenatide on gastric emptying, satiety and satiation in obese participants.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
The Effect of Exenatide on Gastric Emptying in Obese Participants
time frame: up to 30 days
The effect of Exenatide on Gastric Emptying in Obese Participants
time frame: Up to 30 days
Male or female participants from 18 years up to 70 years old.
Inclusion Criteria: - Obese subjects with BMI> 30 Kg/m2: Otherwise healthy individuals who are not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than hyperglycemia not requiring medical therapy) and unstable psychiatric disease. - Age: 18-70 years - Gender: Men or women. Women of childbearing potential will have negative pregnancy test before initiation of medication. - Gastric emptying: Accelerated GE T1/2 < 79 minutes or GE 1h>35 % Exclusion Criteria: - Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria - Unstable heart disease as evidenced by ongoing angina - Congestive heart failure - Concomitant use of appetite suppressants (i.e. caffeine based or diethylpropion) or orlistat (Xenical®) - Uncontrolled hypertension (Blood pressure greater than 160/90 mmHg) - use of anti-diabetic drugs including metformin, - history of nephrolithiasis, - Recurrent major depression, presence or history of suicidal behaviour or ideation with intent to act, and current substantial depressive symptoms (Patient Health Questionnaire [PHQ-9]21 total score ≥10). - Gastroparesis - Inflammatory bowel disease or irritable bowel syndrome - Malignancy treated with chemotherapy within the past 3 years - History of pancreatitis - Renal insufficiency (eGFR less than 50 ml/min) - Concomitant use of MAOI inhibitors (i.e. phenelzine, selegiline), serotonergic agents, and other centrally acting appetite suppressants - Significant psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Scale [HADS] self-administered alcoholism screening test (SAAST, substance abuse) and the questionnaire on eating and weight patterns (binge eating disorders and bulimia). If such a dysfunction is identified by a HADS score ≥11 in any of the subscales or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. - Intake of medication that could interfere with the interpretation of the study or cause drug interaction (i.e. ketoconazole, erythromycin). Specifically, birth control pill, estrogen replacement therapy, and thyroxine replacement are permissible.
|Official title||Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying|
|Principal investigator||Michael Camilleri, MD|
|Description||To evaluate the effect of Exenatide 5mcg SQ twice daily for 30-days on gastric emptying, satiety, satiation and weight loss in obese participants with TCF7L2 "CC compared to TT' genotype.|
Call for more information